Stephen E. Mercer
14Patents
3h-index
31Co-inventors
56Inventor score
Filing activity: Jul 10, 2001 → Jun 26, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7384930B2 | Constrained compounds as CGRP-receptor antagonists | Human Necessities | 17 | Active |
| US7772244B2 | Therapeutic agents for the treatment of migraine | Human Necessities | 9 | Active |
| US7384931B2 | Constrained compounds as CGRP-receptor antagonists | Chemistry; Metallurgy | 6 | Active |
| US6620823B2 | Lactam metalloprotease inhibitors | Chemistry; Metallurgy | 2 | Expired |
| US7125870B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | Chemistry; Metallurgy | 1 | Expired |
| US10799523B2 | Tau antisense oligomers and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US7470679B2 | Constrained compounds as CGRP-receptor antagonists | Chemistry; Metallurgy | 0 | Active |
| US7544680B2 | Constrained compounds as CGRP-receptor antagonists | Human Necessities | 0 | Active |
| US11077132B2 | Tau antisense oligomers and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11058767B2 | CAMK2D antisense oligonucleotides and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7470680B2 | Constrained compounds as CGRP-receptor antagonists | Human Necessities | 0 | Active |
| US11866430B2 | Naphthyridinone compounds useful as T cell activators | Human Necessities | 0 | Active |
| US11761951B2 | Methods of selecting therapeutic molecules | Chemistry; Metallurgy | 0 | Active |
| US9833454B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.